Back to top

Image: Bigstock

Quest Diagnostics Estimates Move Up, Tie-Ups to Add Value

Read MoreHide Full Article

On Jul 11, we issued an updated research report on Quest Diagnostics, Inc. (DGX - Free Report) – a major commercial laboratory services provider.

Ahead of its second-quarter earnings (slated to be released on Jul 21); Quest Diagnostics saw an upward estimate revision for another consecutive quarter of organic growth expectation.   

We note that, Quest Diagnostics has adhered to its five-point strategy that focuses on areas with high potential such as gene-based esoteric testing for cancer, cardiovascular disease, infectious disease and neurological disorders. In the last couple of months, the company has made a number of strategic product launches and formed new partnerships.

This strategic product launches include three new cancer test services that will provide clinically actionable insight into an individual's risk of developing hereditary forms of cancer. These tests will remain part of the company's newly branded Quest Vantage cancer test menu.

We are also looking forward to the company’s recently formed alliance with HealthONE System of HCA Healthcare (HCA - Free Report) to enhance the quality and value of diagnostic services. Per the agreement, Quest Diagnostics will manage in-patient laboratory operations for six Denver-area hospitals in the HealthONE system.

Quest Diagnostics’ other significant partnerships in recent times include the latest alliance with Quintiles, a leading provider of biopharmaceutical development and commercial outsourcing services, Memorial Sloan-Kettering, the University of California, San Francisco and the latest professional lab services relationship with Barnabas Health.

We are also positive on the current favorable demographic trends. Quest Diagnostics’ mergers and acquisitions activity too is on track. In Feb 2016, the company acquired Hartford HealthCare's outreach business under which, it will be paid on a fee-for-service basis by payers at traditional rates. In Aug 2015, the company acquired MemorialCare Health Systems' laboratory outreach services business.

However, through the past several quarters, the overall soft industry trends, responsible for low volume growth, have been a major dampener for the company. This apart, Quest Diagnostics is highly disappointed with the recent CMS proposal related to the Protecting Access to Medicare Act (PAMA). Moreover, lower healthcare utilization continues to be a major deterrent. Although the company has seen signs of modest increase in utilization, sustainability is still a concern.

The stock currently carries a Zacks Rank #2 (Buy).

Key Picks in the Sector

Some better-ranked stocks in the healthcare sector are AmSurg Corp. and BioScrip, Inc. , both holding a Zacks Rank #2 .

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Quest Diagnostics Incorporated (DGX) - free report >>

HCA Healthcare, Inc. (HCA) - free report >>

Published in